

APLYSFISTULARINE: A NOVEL DIBROMOTYROSINE DERIVATIVE ISOLATED FROM *Aplysina fistularis*#

Narlize Silva Lira, Rubens L. Monte-Neto, João Guilherme B. Marchi, Antônio Cláudio da Silva Lins, Josean Fechine Tavares, Marcelo Sobral da Silva, Celidarque da Silva Dias e José Maria Barbosa-Filho*

Departamento de Ciências Farmacêuticas, Universidade Federal da Paraíba, 58051-900 João Pessoa – PB, Brasil

Creusioni Figueredo dos Santos

Departamento de Biologia Molecular, Universidade Federal da Paraíba, 58051-900 João Pessoa – PB, Brasil

Emídio Vasconcelos Leitão da Cunha

Departamento de Farmácia, Universidade Estadual da Paraíba, 58100-000 Campina Grande – PB, Brasil

Ulisses dos Santos Pinheiro

Departamento de Zoologia, Universidade Federal de Pernambuco, 50373-970 Recife – PE, Brasil

Raimundo Braz-Filho

Centro de Ciências e Tecnologia, Universidade Estadual do Norte Fluminense, 28013-600 Campos dos Goytacazes – RJ, Brasil

Recebido em 7/3/12; aceito em 31/7/12; publicado na web em 15/10/12

The new dibromotyrosine derivative 3,5-dibromo-4-[3'dimethylamonium]propoxyphenyl]-*N,N,N*-trimethylethanamonium, here referred to as aplysfistularine (1), was isolated from the marine sponge *Aplysina fistularis* along with 2-(3,5-dibromo-4-methoxyphenyl)-*N,N,N*-trimethylethanamonium (2), aplysterol (3) and 24,28-didehydroaplysterol (4). Their identification was performed by mass spectrometry, infrared, ¹H and ¹³C NMR, and by comparison with literature data. Compound 2 and the mixture of 3 and 4 were tested *in vitro* (inhibitory activity) with supercoiled DNA relaxation techniques, and showed inhibitory activity on human DNA topoisomerase II- α . Compound 1 was not tested due to paucity of the material.

Keywords: *Aplysina fistularis*; aplysfistularine; topoisomerase activity.

INTRODUCTION

A review of recent research reveals that the quest for new drugs is changing direction. Given the ever growing number of natural marine products discovered, researchers have recognized the promising potential of the sea for the chemistry of natural products.¹⁻³ Despite the obstacles to effective development of marine organism-derived pharmaceutical agents, the interest in marine organisms as a new drug source has increased in recent years.⁴⁻¹⁰ Marine sponges are a prolific source of a huge variety of secondary metabolites.¹¹⁻¹⁵ Sponges of the order *Verongida*, and the family Aplysinidae, characterized by the absence of terpenes and the production of steroids, produce a wide diversity of bromotyrosine-containing metabolites with interesting biological properties.¹⁶ The richest sources of biogenetically, tyrosine-derived bromo-containing amines, are members of the *Verongida* order, and the genus *Aplysina*.¹⁷⁻²⁰ Previous and recent reports of *Aplysina fistularis* have documented the presence of a large number of brominated metabolites including: fistularines, aerotionines, ceratinamines, aplysamines, anamonianes and psammaplysinines.²¹⁻²³ The diversity of biological activity found in compounds isolated from marine sponges is due to the presence of bromotyrosine derivatives. In the case of the order *Verongida*, many of the species produce compounds with antimicrobial, antibacterial, cytotoxic and antitumor activity.^{23,24}

Nuclear enzymes that control and modify the topological states of DNA are known as topoisomerases. In mammalian cells, they are classified into types I and II, according to their mechanisms and physical properties. Topoisomerase II (Topo II), a dimer composed of two isoforms with a total size of 170 KDa, is responsible for separating the double DNA helix, leading to events such as DNA release, transcription,

chromosome condensation and recombination.²⁵⁻²⁸ During cell proliferation, topoisomerases take part in DNA maintenance and replication. When these functions are deactivated, cells become vulnerable. Furthermore, the expression of DNA Topo I and II is higher in tumors than in normal cells.²⁹ Topoisomerase II inhibitors with anticancer and antiviral potential are important targets in the development of new drugs.³⁰ In an attempt to discover new topoisomerase inhibitors, many classes of natural products have been tested and described in the literature, including flavonoids,³¹ biflavonoids,³² diterpenes,³³ triterpenoids,³⁴ estilbenoids,³⁵ alkaloids,³⁶⁻³⁹ naphthodianthrones,⁴⁰ naphthoquinones,⁴¹ binaphthoquinones,⁴² polyunsaturated fatty acids,⁴³ derivatives of the chromone nucleus, and many substances isolated from plants.⁴⁴ In medicine, compounds from the anthracycline and epipodophyllotoxin classes stand out as potent topoisomerase II inhibitors. These act by inhibiting DNA rebinding, and inducing the binding of proteins at breaks, constituting part of first line chemotherapy for a large variety of solid and hematological tumors. Etoposide, a semisynthetic derivative of the lignan podophyllotoxin, plays an important role in clinical treatments as a chemotherapeutic agent for a variety of tumors, including carcinomas, testicular cancer and lymphomas.⁴⁵

According to Rhee *et al.*⁴⁶ one of the main structural requirements for Topo II inhibition is the presence of a planar chromophore in aromatic rings. Substances with this kind of chromophore can intercalate with DNA causing blockage or enzymatic reading errors during the replication process. Metabolite 2 has called our attention for presenting planar chromophores in aromatic rings, and this structural feature might confer inhibitory activity for the topoisomerase enzyme.

The work with *A. fistularis* led to the isolation of four substances: the dibromotyrosine derivatives 3,5-dibromo-4-[3'dimethylamonium]propoxyphenyl]-*N,N,N*-trimethylethanamonium also known as aplysfistularine (1) and 2-(3,5-dibromo-4-methoxyphenyl)-*N,N,N*-trimethylethanamonium (2), along with aplysterol (3) and 24,28-didehydroaplysterol (4).

*e-mail: jbarbosa@lft.ufpb.br

#Artigo em homenagem ao Prof. Otto R. Gottlieb (31/8/1920-19/6/2011)

RESULTS AND DISCUSSION

Structural analysis and determination

All the substances were identified by means of their NMR, mass, and infrared spectroscopic data, as well as by comparison with the literature (Figure 1).




Figure 1. Chemical constituents from the sponge *Aplysina fistularis*

Compound **1** was obtained as an amorphous, yellow solid. Analysis of the molecular formula $C_{16}H_{27}ON_2Br_2$ by HRESIMS revealed the fragment m/z 426.0095 referring to a molecular ion peak. The absorption spectrum in the IR region revealed the presence of absorption bands at 3003-2816, 1300-1100 and at 1591-1412 cm^{-1} , indicative of the presence of saturated C-H bonds, aromatic ethers, and aromatic rings C=C, respectively.^{47,48} The 1H NMR spectrum showed a singlet at δ_H 7.32, suggesting a substituted aromatic system for compound **1**. The presence of a singlet at δ_H 2.32 integrating to nine hydrogens referring to three *N*-methyl groups, and two multiplets at δ_H 2.59 and 2.71 with integral for two hydrogens each, suggested the presence of an *N,N,N*-trimethylethylammonium group. In the same spectrum, another singlet at δ_H 2.49 corresponding to six hydrogens from two other *N*-methyl groups; two other multiplets of two protons each at δ_H 2.15 and 2.89, referring to methylene hydrogens; as well as the presence of a triplet with integral to two H at δ_H 4.01, referring to the oxymethylenic H, suggests the existence of an *N,N*-dimethylammonium-propanol group. The NMR spectrum of ^{13}C -APT showed eleven spectral signals, four of which (δ_C 151.30; 138.58; 132.80 and 118.02) were present in the high-frequency region, suggesting a tetra-substituted benzene ring. Signals at δ_C 132.80; 60.20; 44.74 (C-2/6, C-8 and 9- $N^+(Me)_3$, respectively), as well as others at δ_C 71.00; 26.79; 55.77 and 44.06 (C-1', C-2', C-3' and 4'- $NH^+(Me)_2$, respectively) corroborated the indication of the 1H NMR spectra for the presence of *N,N,N*-trimethylethylammonium and *N,N*-dimethylammonium-propanol, respectively. In COSY two-dimensional spectrum, we observed a correlation between signals at

δ_H 2.71 and δ_H 2.59, which allowed us to identify methylene hydrogens from positions seven and eight, respectively, and suggest the presence of an *N,N,N*-trimethylethylammonium group. A correlation between signals at δ_H 4.01 and δ_H 2.15, and the signal at δ_H 2.89 also allowed the assignment of oxymethylene hydrogens from positions H-1', H-2' and H-3' and proposal of the presence of *N,N,N*-trimethylethylammonium and *N,N*-dimethylammonium-propanol. The HMBC correlation spectrum confirmed previous assignments, and allowed us to define the position of substitution in the benzene ring. A two-bond correlation between signals at δ_H 2.71 (H-7) and δ_C 138.58 (C-1), as well as a three-bond correlation between signals at δ_H 7.32 (H-2/6) and δ_C 32.26 (C-7) allows us to affirm that an *N,N,N*-trimethylethylammonium group is inserted into position 1 of the benzene ring. We also observed a three-bond correlation between signals of H-2/6 (δ_H 7.32) and of C-4 (δ_C 151.30), which permitted us to infer that the oxygenated group *N,N*-dimethylammonium-propanol is inserted into position 4, since C-4 is deshielded compared to other carbons of the benzene ring (Table 1). Spectral data analysis of 1H and ^{13}C NMR of compound **1** allowed us to identify it as a dibromotyrosine derivative, whose chemical name is 3,5-dibromo-4-[3'-dimethylammonium]propoxyphenyl]-*N,N,N*-trimethylethylammonium, which was denominated "Aplysifistularine" (**1**).

In vitro assay for inhibitory activity against human DNA topoisomerase II- α

The presence of the planar chromophore, due to the aromatic ring, confers compound **2** the possibility of interacting with the Topo II- α enzyme. Due to this structural feature, we evaluated the possible action of **2** on the human DNA Topo II- α from DNA plasmid relaxation assays. Compound **1** was not tested for Topoisomerase II- α activity due to the paucity of the material for the experiments.

Figure 2 shows the catalytic activity inhibition for the enzyme DNA topoisomerase II- α , observed *in vitro* with plasmid DNA (pBR322) relaxation in the presence of ATP and Mg^{2+} . Both the steroid mixture (aplysterol/24,28-didehydroaplysterol), and compound **2** exhibited complete Topo II- α inhibition at 100 μM concentrations, as can be seen on lanes 5 in Figures 2B and 2C, respectively. In Figure 2C, no Topo II- α inhibition is evident at 25, 12 and 1 μM concentrations. This result was compared with etoposide, a well-known inhibitor specific to Topo II- α , which was used as a control (100 μM), and presents a similar profile to that observed for the steroid mixture and compound **2** (Figures 2B and 2C). The minimum concentration for inhibitory activity was determined as 50 μM for the steroid mixture tested (lane 4 of Figure 2B).

Compound **2** and the steroid mixture showed inhibitory activity against human DNA-Topo II- α , and would be a good prototype for future investigations for new anti-tumor agents.

EXPERIMENTAL

Instruments

Infrared (IR) spectra were registered in KBr pellets, on a Bomem model MB 100 spectrophotometer. Mass spectra were obtained on a Q-TOF-Micromass mass spectrometer with analysis by Electrospray Ionization (+) on a hybrid Quadrupole Time of Flight (QTOF) device. Samples were dissolved and diluted in a methanol: H_2O (1:1) solution with formic acid at 0.01% to the concentration of 1.0 $\mu g mL^{-1}$. The spectra were obtained in positive ion mode. The injection flow was 1.0 $mL min^{-1}$. One and two-dimensional NMR of 1H and ^{13}C spectra were obtained on a Bruker spectrometer NMR (DRX 500), and Varian System spectrometer NMR (500) operating at 500 MHz (1H)




Figure 2. Inhibitory activity of Human DNA Topoisomerase II- α by chemical constituents of the marine sponge *Aplysina fistularis*. (A) 0.125 $\mu\text{g}/\text{mL}^{-1}$ of DNA supercoiled plasmid pBR322 electrophoresed in 1% agarose gel alone (lane 1A); 0.125 $\mu\text{g}/\text{mL}^{-1}$ of Human DNA with 1.0 unit of Topo II- α enzyme (lane 2A), negative control or treated with both 0.125 $\mu\text{g}/\text{mL}^{-1}$ of Human DNA, 1.0 unit of Topo II- α enzyme and its inhibitor 100 μM Etoposide (lane 3A) as positive control. Plasmid incubated with enzyme and several concentrations of steroids mixture (Aplysterol and 24-28-didehydroaplysterol) (B) or Compound 2 (C), from *A. fistularis*. Concentrations from 1 to 100 μM for each inhibitor candidate. With exception of lane 1A, all lanes contain 0.125 $\mu\text{g}/\text{mL}^{-1}$ of the plasmid DNA pBR322 and 1.0 unit of TopoII- α enzyme

and at 125 MHz (^{13}C). Deuterated solvents from Cambridge Isotope Laboratories were used (CIL) (CDCl_3 , CD_3OD).

Collection, processing and fractionation of *Aplysina fistularis*

The sponge *A. fistularis* was collected in the sea canyons of the State of Paraiba, Brazil. The species were registered under numbers 63 and 65, and deposited in the Paulo Yang Marine Invertebrates Collection, at the Department of Systematics and Ecology of the Universidade Federal da Paraiba. As soon as they were collected, the specimens were preserved in ethanol. The crude ethanol extract was equivalent to 16.65% of the dry weight of the sponges. This extract was subjected to a liquid-liquid partition with hexane, dichloromethane and ethyl acetate. The dichloromethane fraction was subjected to a series of Column chromatography over Sephadex LH-20 (pure methanol as eluent) and also silica gel (gradients of methanol:dichloromethane or methanol:ethyl acetate). The fractions containing the dibromotyrosine derivatives (detected by TLC under UV light 254 nm) were purified by column chromatography over silica gel using a gradient of methanol:dichloromethane. The chromatographic fractionation of the ethanol extract of the sponge *A. fistularis* yielded the newly isolated 1, the known substance 2 and a mixture of the steroids 3 and 4, at a 1:1 proportion.

Aplysistularine (1)

Amorphous yellow solid; Solubility: chloroform; $\text{C}_{16}\text{H}_{27}\text{ON}_2\text{Br}_2$; Mol. wt.: 426.00 u.m.a; IR (KBr) ν_{max} 3426, 3003, 2976, 2938, 2862, 2816, 2335 1300-1100, 1259, 1440-1600 cm^{-1} ; ^1H and ^{13}C NMR data, Table 1; HRESIMS: m/z 204.0344; m/z 205.0240 (molecular ion); m/z 206.0330; m/z 252.0204; m/z 423.0365; m/z 425.0173; m/z 426.0095.

2-(3,5-Dibromo-4-methoxyphenyl)-*N,N,N*-trimethylethanammonium (2)

Amorphous yellow solid; Solubility: methanol; $\text{C}_{12}\text{H}_{18}\text{Br}_2\text{NO}$; Mol. wt.: 352.08 u.m.a; IR (KBr) ν_{max} 3426, 3003, 2976, 2938, 2862, 2816, 2335, 1440-1600; 1300-1100, 1259 (cm^{-1}); ^1H and ^{13}C NMR data, Table 1; HRESIMS: m/z 349.9877; m/z 351.9876 (molecular

Table 1. NMR data of ^1H (500 MHz) and ^{13}C (125 MHz) for compounds 1 and 2 (δ in ppm)

	1 (Measured in CDCl_3)				2 (Measured in CD_3OD)			
	HMQC		HMBC		HMQC		HMBC	
	δ_{C}	δ_{H}	$^2J_{\text{CH}}$	$^3J_{\text{CH}}$	δ_{C}	δ_{H}	$^2J_{\text{CH}}$ e $^3J_{\text{CH}}$	
C								
1	138.58	-	2H-7	-	136.32	-	H-2/H-6; 2H-7; 2H-8	
3/5	118.02	-	H-2/H-6	-	119.38	-	H-2/H-6	
4	151.30	-	-	H-2/H-6	154.90	-	H-2/H-6; MeO-4	
CH								
2/6	132.80	7.32, s	-	2H-7	134.80	7.64, s	2H-7	
CH₂								
7	32.26	2.71, m	2H-8	H-2/H-6	28.98	3.12, m	2H-8	
8	60.20	2.59, m	2H-7	$\text{Me}_3\text{N}-8$	67.80	3.58, m	$\text{Me}_3\text{N}-8$	
1'	71.00	4.01, (<i>t</i> , $J=6.0$ Hz)	2H-2'	2H-3'	-	-	-	
2'	26.79	2.15, m	2H-1'; 2H-3'	-	-	-	-	
3'	55.77	2.89, m	-	2H-1'; $\text{Me}_2\text{N}-3'$	-	-	-	
NMe₂/NMe₃								
9	44.74	2.32, s	-	2H-8	53.96 53.93 53.91	3.23, s	-	
4'	44.06	2.49, s	-	2H-1'	-	-	-	
MeO								
4	-	-	-	-	61.35	3.85, s	-	

ion); m/z 378.9383; m/z 380.9276. NMR data agreed with the literature values.^{12,49}

Aplysterol I Amorphous white solid; Solubility: chloroform; $C_{29}H_{50}O$; Mol.wt.: 414 u.m.a; NMR data agreed with the literature values.⁵⁰

24,28-Didehydroaplysterol (4)

Amorphous white solid; Solubility: Chloroform; $C_{29}H_{48}O$; Mol.wt.: 412 u.m.a; NMR data agreed with the literature values.⁵⁰

In vitro assay for topoisomerase II- α

The conversion of *pBR322* supercoiled plasmid DNA to the relaxed form by the enzymes topoisomerase II- α was examined. The DNA relaxation assay was analyzed by following the protocol described by topoGEN (topoGEN, Columbus, OH, USA). One unit of topo II- α (human recombinant in *E. coli*, USB Corporation) enzymes were incubated with $0.125 \mu\text{g}/\text{mL}^{-1}$ of *pBR322* DNA (Invitrogen), in the presence of $100 \mu\text{M}$ of compound **2**, and of the steroid mixture separately, or (in the absence of the test compounds) in $10 \mu\text{L}$ of a mixture containing 10 mM Tris, $\text{pH } 7.9$, 50 mM NaCl, 50 mM KCl, 5 mM MgCl_2 , 0.1 mM EDTA, $15 \mu\text{g}$ mM BSA and 1 mM ATP, 10 mM Na_2HPO_4 and 0.2 mM DTT for 40 min at 37°C . The reaction was stopped by the addition of $1 \mu\text{L}$ of a solution consisting of 10% sodium dodecyl sulfate (SDS) and 25% bromophenol blue and 50% glycerol. Etoposide was used as the positive control. Electrophoresis was carried out over 1% agarose gel plates, in TAE buffer, at $\text{pH } 8.5$, for 120 min at 40 V .

CONCLUSION

The chemical study of *A. fistularis* led to the isolation of a new dibromotyrosine derivative: Aplysfistularine, and its first description in the literature. Since the isolated compounds in this paper are considered to be chemotaxonomic markers of the species, we believe it to be an important contribution to the study of the species.

The substances isolated from *A. fistularis* inhibited the action of human DNA topoisomerase II- α at concentrations of 50 and $100 \mu\text{M}$. Further biological evaluations are in progress to determine the compound's potency. Due to their great diversity, marine sponges represent a promising source of secondary metabolites. This study shows their importance for natural product chemistry and pharmacology by presenting compounds isolated from *A. fistularis* with inhibitory activity on the human topoisomerase II- α DNA enzyme.

SUPPLEMENTARY MATERIAL

^1H and ^{13}C NMR spectra, COSY, HMQC, HMBC, NOESY spectra, and HRESIMS spectra of compounds **1** and **2** as well as the HSQC-TOCSY spectra of compound **1** are available at <http://quimicanova.s bq.org.br>, in PDF file, with free access.

ACKNOWLEDGEMENTS

This work was financially supported by CNPq/FAPESQ/PRONEX/INCTAmTropic-Brazil. We are also extremely grateful to NUCAL/LTF and CENAUREM/UFC for conducting the spectra of 500 MHz . The authors are also grateful to the technicians V. C. de O. Costa, Raimundo N. da Silva Filho and D. E. de A. Uchoa for the technical support.

REFERENCES

1. Costa-Lotufó, L. V.; Wilke, D. V.; Jimenez, P. C.; Epifanio, R. A.; *Quim.*

- Nova* **2009**, *32*, 703.
2. Kossuga, M. H.; Lira, S. P.; McHugh, S.; Yohandra, R.; Torres, Y. R.; Lima, B. A.; Gonçalves, R.; Veloso, K.; Ferreira, A. G.; Rocha, R. M.; Berlinck, R. G. S.; *J. Braz. Chem. Soc.* **2009**, *20*, 704.
3. Almeida, C. L. F.; Falcão, H. S.; Lima, G. R. M.; Montenegro, C. A.; Lira, N. S.; Athayde-Filho, P. F.; Rodrigues, L. C.; Souza, M. F. V.; Barbosa-Filho, J. M.; Batista, L. M.; *Int. J. Mol. Sci.* **2011**, *12*, 4550.
4. Souza, E. T.; Lira, D. P.; Queiroz, A. C.; Silva, D. J. C.; Aquino, A. B.; Mella, E. A. C.; Lorenzo, V. P.; Miranda, G. E. C.; Araújo-Júnior, J. X.; Chaves, M. C. O.; Barbosa-Filho, J. M.; Athayde-Filho, P. F.; Santos, B. V. O.; Alexandre-Moreira, M. S.; *Mar. Drugs* **2009**, *7*, 689.
5. Garcia, D. G.; Bianco, E. M.; Santos, M. C. B.; Pereira, R. C.; Faria, M. V. C. F.; Teixeira, V. L.; Burth, P.; *Phytother. Res.* **2009**, *23*, 943.
6. Silva, C. T. C.; Hernández, L. C.; Reyes, O. E. O.; Rodríguez, F. A. R.; Beltrán, C. D.; Hegedus, M. P.; *Quim. Nova* **2010**, *33*, 656.
7. Paula, J. C.; Vallim, M. A.; Teixeira, V. L.; *Rev. Bras. Farmacogn.* **2011**, *21*, 216.
8. Matta, C. B. B.; Souza, E. T.; Queiroz, A. C.; Lira, D. P.; Araújo, M. V.; Cavalcante-Silva, L. H. A.; Miranda, G. E. C.; Araújo-Júnior, J. X.; Barbosa-Filho, J. M.; Santos, B. V. O.; Alexandre-Moreira, M. S.; *Mar. Drugs* **2011**, *9*, 307.
9. Bitencourt, M. A. O.; Dantas, G. R.; Lira, D. P.; Barbosa-Filho, J. M.; Miranda, G. E. C.; Santos, B. V. O.; Souto, J. T.; *Mar. Drugs* **2011**, *9*, 1332.
10. Queiroz, T. M.; Machado, N. T.; Furtado, F. F.; Oliveira-Filho, A. A.; Alustau, M. C.; Figueiredo, C. S.; Miranda, G. E. C.; Barbosa-Filho, J. M.; Braga, V. A.; Medeiros, I. A.; *Mar. Drugs* **2011**, *9*, 2075.
11. Almeida, A. M. P.; Berlinck, R. G. S.; Hajdu, E.; *Quim. Nova* **1997**, *20*, 170.
12. Granato, A. C.; Berlinck, R. G. S.; Magalhães, A.; Schefer, A. B.; Ferreira, A. G.; Sanctis, B.; Freitas, J. C.; Hajdu, E.; Migotto, A. E.; *Quim. Nova* **2000**, *23*, 594.
13. Epifanio, R. A.; Pinheiro, L. S.; Alves, N. C.; *J. Braz. Chem. Soc.* **2005**, *16*, 1367.
14. Lira, S. P.; Selegim, M. H. R.; Williams, D. E.; Marion, F.; Hamill, P.; Jean, F.; Andersen, R. J.; Hajdu, E.; Berlinck, R. G. S. J.; *Braz. Chem. Soc.* **2007**, *18*, 440.
15. Regalado, E. L.; Laguna, A.; Mendiola, J.; Thomas, O. P.; Nogueiras, C.; *Quim. Nova* **2011**, *34*, 289.
16. Kochanowska, A. J.; Rao, K. V.; Childress, S.; El-Alfy, A.; Matsumoto, R. R.; Kelly, M.; Stewart, G. S.; Sufka, K. J.; Hamann, M. T.; *J. Nat. Prod.* **2008**, *71*, 186.
17. Ciminiello, P.; Fattorusso, E.; Magno, S.; Magno, A.; *J. Nat. Prod.* **1994**, *57*, 1564.
18. Ciminiello, P.; Dell'Aversano, C.; Fattorusso, E.; Magno, S.; Pansini, M.; *J. Nat. Prod.* **2000**, *63*, 263.
19. Granato, A. C.; Oliveira, J. H. L.; Selegim, M. H. R.; Berlinck, R. G. S.; Macedo, M.; Ferreira, A. G.; Rocha, R. M.; Hajdu, E.; Peixinho, S.; Pessoa, C. O.; Moraes M. O.; Cavalcanti, B. C.; *Quim. Nova* **2005**, *28*, 192.
20. Lira, T. O.; Berlinck, R. G. S.; Nascimento, G. G. F.; Hajdu, E.; *J. Braz. Chem. Soc.* **2006**, *17*, 1233.
21. Ciminiello, P.; Constantino, V.; Fattorusso, E.; Magno, S.; Mangoni, A.; *J. Nat. Prod.* **1994**, *57*, 705.
22. Thoms, C.; Ebel, R.; Proksch, P.; *J. Chem. Ecol.* **2005**, *32*, 97.
23. Gandolfi, R. C.; Medina, M. B.; Berlinck, R. G. S.; Lira, S. P.; Galetti, F. C. S.; Silva, C. L.; Veloso, K.; Ferreira, A. G.; Hajdu, E.; Peixinho, S.; *Quim. Nova* **2010**, *33*, 1853.
24. Saeki, B. M.; Granato, A. C.; Berlinck, R. G. S.; Magalhães, A.; Schefer, A. B.; Ferreira, A. G.; Pinheiro, U. S.; Hajdu, E.; *J. Nat. Prod.* **2002**, *65*, 796.
25. Constantinou, A.; Mehta, R.; Runyan, C.; Rao, K.; Vaughan, A.; Moon, R.; *J. Nat. Prod.* **1995**, *58*, 217.

26. Shi, Q.; Chen, K.; Li, L.; Chang, J.; Autry, C.; Kozuka, M.; Konoshima, T.; Estes, J. R.; Lin, C. M.; Hamel, E.; McPhail, D. R.; Lee, K.; *J. Nat. Prod.* **1995**, *58*, 475.
27. Olano, C.; Méndez, C.; Salas, J. A.; *Mar. Drugs* **2009**, *7*, 210.
28. Chan, A. L.-F.; Chang, W.-S.; Chen, L.-M.; Lee, C.-M.; Chen, C.-E.; Lin, C.-M.; Hwang, J.-L.; *Molecules* **2009**, *14*, 1342.
29. Grynberg, N. F.; Carvalho, M. G.; Velandia, J. R.; Oliveira, M. C.; Moreira, I. C.; Braz-Filho, R.; Echevarria, A.; *Braz. J. Med. Biol. Res.* **2002**, *35*, 819.
30. Maciel, M. A. M.; Martins, J. R.; Pinto, A. C.; Kaiser, C. R.; Esteves-Souza, A.; Echevarria, A.; *J. Braz. Chem. Soc.* **2007**, *18*, 391.
31. Zhou, N.; Yan, Y.; Li, W.; Wang, Y.; Zheng, L.; Han, S.; Yan, Y.; Li, Y.; *Int. J. Mol. Sci.* **2009**, *10*, 3255.
32. Bahia, M. V.; Santos, J. B.; David, J. P.; David, J. M.; *J. Braz. Chem. Soc.* **2005**, *16*, 1402.
33. Meragelman, T. L.; Silva, G. L.; Mangelli, E.; Gil, R. R.; *Phytochemistry* **2003**, *62*, 569.
34. Wada, S.; Tanaka, R.; Lida, A.; Matsunaga, S.; *Bioorg. Med. Chem. Lett.* **1998**, *8*, 2829.
35. Branco, A.; Pinto, A. C.; Braz-Filho, R.; Silva, E. F.; Grynberg, N. F.; Echevarria, A.; *Rev. Bras. Farmacogn.* **2008**, *18*, 703.
36. Kim, S. I.; Lee, S. H.; Lee, E. S.; Lee, C. S.; Jahng, Y.; *Arch. Pharm. Res.* **2012**, *35*, 785.
37. Baunbæk, D.; Trinkler, N.; Ferandin, Y.; Lozach, O.; Ploypradith, P.; Rucirawat, S.; Ishibashi, F.; Iwao, M.; Meijer, L.; *Mar. Drugs* **2008**, *6*, 514.
38. Deslandes, S.; Chassaing, S.; Delfourne, E.; *Mar. Drugs* **2009**, *7*, 754.
39. Marshall, K. M.; Andjelic, C. D.; Tasdemir, D.; Concepción, G. P.; Ireland, C. M.; Barrows, L. R.; *Mar. Drugs* **2009**, *7*, 196.
40. Peebles, K. A.; Baker, R. K.; Kurz, E. U.; Schneider, B. J.; Kroll, D. J.; *Biochem. Pharmacol.* **2001**, *62*, 1059.
41. Esteves-Souza, A.; Figueiredo, D. V.; Esteves, A.; Câmara, C. A.; Vargas, M. D.; Pinto, A. C.; Echevarria, A.; *Braz. J. Med. Biol. Res.* **2007**, *40*, 1399.
42. Ting, C.; Hsu, C.; Hsu, H.; Su, J.; Chen, T.; Tarn, W.; Kuo, Y.; Whang-Peng, J.; Liu, L. F.; Hwang, J.; *Biochem. Pharmacol.* **2003**, *66*, 1981.
43. Yonezawa, Y.; Yoshida, H.; Mizushima, Y.; *Int. J. Mol. Sci.* **2007**, *8*, 1206.
44. Ishar, M. P. S.; Singh, G.; Singh, S.; Sreenivasan, K. K.; Singh, G.; *Bioorg. Med. Chem. Lett.* **2006**, *16*, 1366.
45. De Vita Jr., V. T.; Hellman, S.; Rosenberg, S. A.; *Cancer - Principles of Practice of Oncology*, 5th ed., Lippincott-Raven: Philadelphia, 1997.
46. Rhee, H.; Park, H. J.; Lee, S. K.; Lee, C.; Choo, H. P.; *Bioorg. Med. Chem.* **2007**, *15*, 1651.
47. Silverstein, R. M.; Bassler, G. P. C.; Morrill, T. C.; *Identificação Espectrométrica de Compostos Orgânicos*, 7^a ed., Guanabara Koogan: Rio de Janeiro, 2007.
48. Pavia, D. L.; Lampman, G. M.; Kriz, G. S.; *Introduction to Spectroscopy*, 2nd ed., Saunders College Publishing: Washington, 2001.
49. Kossuga, M. H.; Lira, S. P.; Nascimento, A. M.; Gambardella, M. T. P.; Berlink, R. G. S.; Torres, Y. H.; Nascimento, G. G. F.; Pimenta, E. F.; Silva, M.; Thiemann, O. H.; Oliva, G.; Tempore, A. G.; Melhem, M. S. C.; Souza, A. O.; Galetti, F. C. S.; Silva, C. L.; Cavalcanti, B.; Pessoa, C. O.; Moraes, M. O.; Hadju, E.; Peixinho, S.; Rocha, R. M.; *Quim. Nova* **2007**, *30*, 1194.
50. Kelecom, A.; Kannengiesser, G. J.; Baker, P. M.; *An. Acad. Bras. Cienc.* **1979**, *51*, 643.